24-hour IOP monitoring

Article

A Swiss startup company, Sensimed, has developed a novel technology for measuring increases in intraocular pressure.

A novel technology for 24-hour IOP monitoring has been developed during which time the patient's movements are unrestricted. The system is designed to monitor intraocular pressure (IOP) continuously, up to 24 hours and comprises a soft hydrophilic silicone disposable contact lens embedding a MEMS sensor (micro electro-mechanical system) and a telemetry microprocessor.

Abnormal IOL is one of known causes of glaucoma. This behavior is individual, has transient peaks and varies significantly over a 24-hours period. The system, The Triggerfish, developed by a Swiss start-up company, SENSIMED, has received its CE mark and will undergo clinical trials during 2009 in key European centres. In the US it is under FDA review.

"With one of two glaucoma patients undiagnosed and one of three under inadequate treatment, we believe this will be a great contribution to help ophthalmologists diagnose and treat their glaucoma patients." said Jean-Marc Wismer, CEO of SENSIMED. "A better understanding of how pressure fluctuates during night and day in a patient suffering from glaucoma will lead, for the first time, to more efficient and personalized drug delivery. The breakthrough potential of the solution is enormous and confirmed by the eagerness of our key opinion leaders."

In addition to the medical device system, SENSIMED has developed a full, generic telemetry solution which can be adapted to interface various types of sensors for a variety of applications. The principle is to enable in situ measurement without physical connection or power supply on the sensing site. An external system will send RF (radio-frequency) power to the sensing site and receive in return measurement information.

www.sensimed.ch

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
© 2025 MJH Life Sciences

All rights reserved.